Baird analyst David Rescott downgraded Penumbra (PEN) to Neutral from Outperform with a price target of $374, up from $345. The firm cites the pending acquisition by Boston Scientific for the downgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN: